You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
The US Food and Drug Administration said it plans to aggressively pursue companies selling unproven products for diagnosing, preventing, or treating COVID-19.
Cepheid's Xpert Xpress SARS-CoV-2 rapid molecular diagnostic test can be used in high- and moderate-complexity labs and at the point of care in certain settings.
Test makers are preparing to ramp up production of new SARS-CoV-2 assays and designated testing systems in anticipation of increased demand.
The companies are working together to secure US Food and Drug Administration Emergency Use Authorization for the digital droplet PCR test.
The ePlex SARS-CoV-2 Test is exclusively for use on the company's ePlex sample-to-answer system, which has a global installed base of more than 500 as of the end of 2019.
The test will run on the m2000 RealTime molecular system, and the company said it will be shipping 150,000 tests immediately.
The EUA is the fifth in less than a week from the FDA for assays to detect SARS-CoV-2 as testing capacity in the US continues to ramp up.
In a guidance, the agency described expanded policies that will enable manufacturers, local labs, and others to quickly deploy coronavirus testing.
Hologic and LabCorp became the third and fourth commercial test makers to receive EUA designation for assays to detect the coronavirus that causes COVID-19.
The sponsors of the VALID Act say it's time to modernize outdated diagnostic regulations slowing down test access during a public health crisis.
Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.
Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.
The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.
In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.